Nevertheless, the JUNIPER trial [59] and the SWOG S1400C study [60], which tested the efficacy of abemaciclib and palbociclib as single agents, did not show great activity of CDK 4/6 inhibitors in mutant KRAS NSCLC tumors (Table 3). Here, KRAS is linked to non-small cell lung carcinoma.